In a newly published study an association between cannabis-based medicinal products and improvements in anxiety, sleep quality, and general health-related quality of life was observed in patients with attention-deficit/hyperactivity disorder (ADHD).
Published in the journal Neuropsychopharmacology Reports, the study was conducted by researchers at Imperial College London, Sapphire Medical Clinics and King’s College London.
“This study aims to analyze the health-related quality of life (HRQoL) and safety outcomes in attention-deficit/hyperactivity disorder (ADHD) patients treated with cannabis-based medicinal products (CBMPs)”, states the study’s abstract.
Continue reading